Karthik V. Giridhar

TL;DR: The discovery of the first potent and selective cell-active small molecule inhibitor for PKD, benzoxoloazepinolone (CID755673), which inhibited the known biological actions of PKD1 including phorbol ester-induced class IIa histone deacetylase 5 nuclear exclusion, vesicular stomatitis virus glycoprotein transport from the Golgi to the plasma membrane, and the ilimaquinone-induced Golgi fragmentation.

TL;DR: Modifications to the aromatic core structure in particular significantly increased potency while retaining high specificity for PKD and caused a dramatic arrest in cell proliferation accompanying elevated cytotoxicity when applied to prostate cancer cells.

TL;DR: Male breast cancer (MBC) is a rare disease for which there is limited understanding of treatment patterns and prognostic factors and there is a need to understand more about how these patterns are changed over time.

TL;DR: Current knowledge of the biology and clinicopathology of male breast cancer is summarized and current approaches to locoregional and systemic management of this rare disease are reviewed.

TL;DR: Further validation of miRNA-based prognostic biomarkers are needed to improve current clinic-pathologic based prognostic models in patients with mRCC.